$1.18
-0.05 (-4.07%)
Open$1.21
Previous Close$1.23
Day High$1.28
Day Low$1.17
52W High$7.04
52W Low$0.90
Volume—
Avg Volume107.0K
Market Cap48.93M
P/E Ratio—
EPS$-10.60
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,771.2% upside
Current
$1.18
$1.18
Target
$22.08
$22.08
$13.69
$22.08 avg
$22.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.10M | 11.96M | 10.98M |
| Net Income | 3.15M | 2.42M | 2.50M |
| Profit Margin | 26.0% | 20.2% | 22.8% |
| EBITDA | 4.53M | 4.37M | 3.74M |
| Free Cash Flow | 1.56M | 1.43M | 1.67M |
| Rev Growth | +0.7% | +19.7% | +24.9% |
| Debt/Equity | 0.93 | 0.73 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |